Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

SIMPLE SUMMARY: The combination of venetoclax and azacititine (VEN–AZA) has recently been approved for the treatment of unfit newly diagnosed (ND) acute myeloid leukemia (AML) patients. Few data are available for the relapsed and/or refractory (R/R) AML group. We retrospectively compared the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Garciaz, Sylvain, Hospital, Marie-Anne, Alary, Anne-Sophie, Saillard, Colombe, Hicheri, Yosr, Mohty, Bilal, Rey, Jérôme, D’Incan, Evelyne, Charbonnier, Aude, Villetard, Ferdinand, Maisano, Valerio, Lombardi, Laura, Ittel, Antoine, Mozziconacci, Marie-Joelle, Gelsi-Boyer, Véronique, Vey, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028084/
https://www.ncbi.nlm.nih.gov/pubmed/35454930
http://dx.doi.org/10.3390/cancers14082025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028084/
https://www.ncbi.nlm.nih.gov/pubmed/35454930
http://dx.doi.org/10.3390/cancers14082025

Ejemplares similares